References
1. Thomson G. COVID-19: social distancing, ACE 2 receptors, protease inhibitors and beyond? Int J Clin Pract 2020: e13503.
2. Yang X, Yu Y, Xu J et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020.
3. Guan WJ, Ni ZY, Hu Y et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020.
4. Zhang JJ, Dong X, Cao YY et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020.
5. Team TNCPERE. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus disease (COVID-19)-China, 2020. Available at: http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51 Last accessed on March 7, 2020. China CDC Weekly 2020;2020, 2(8): 113-122 .
6. Wang D, Hu B, Hu C et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama 2020.
7. Roca-Ho H, Riera M, Palau V et al. Characterization of ACE and ACE2 Expression within Different Organs of the NOD Mouse. Int J Mol Sci 2017; 18 .
8. Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci 2004; 25 : 291-4.
9. Mossel EC, Wang J, Jeffers S et al. SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells.Virology 2008; 372 : 127-35.
10. Donoghue M, Hsieh F, Baronas E et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87 : E1-9.
11. Gembardt F, Sterner-Kock A, Imboden H et al. Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents.Peptides 2005; 26 : 1270-7.
12. Kuba K, Imai Y, Rao S et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.Nat Med 2005; 11 : 875-9.
13. Ren X, Glende J, Al-Falah M et al. Analysis of ACE2 in polarized epithelial cells: surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus. J Gen Virol2006; 87 : 1691-5.
14. Han DP, Lohani M, Cho MW. Specific asparagine-linked glycosylation sites are critical for DC-SIGN- and L-SIGN-mediated severe acute respiratory syndrome coronavirus entry. J Virol 2007;81 : 12029-39.
15. Kuhn JH, Li W, Choe H, Farzan M. Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus. Cell Mol Life Sci 2004;61 : 2738-43.
16. Li W, Moore MJ, Vasilieva N et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426 : 450-4.
17. Wong SK, Li W, Moore MJ et al. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2.J Biol Chem 2004; 279 : 3197-201.
18. Guo YR, Cao QD, Hong ZS et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res 2020; 7 : 11.
19. Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun 2020.
20. Wrapp D, Wang N, Corbett KS et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020;367 : 1260-3.
21. Song W, Gui M, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathog 2018; 14 : e1007236.
22. Bosch BJ, van der Zee R, de Haan CA, Rottier PJ. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol2003; 77 : 8801-11.
23. Beniac DR, deVarennes SL, Andonov A et al. Conformational reorganization of the SARS coronavirus spike following receptor binding: implications for membrane fusion. PLoS One 2007; 2 : e1082.
24. Li F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol 2016; 3 : 237-61.
25. Hamming I, Cooper ME, Haagmans BL et al. The emerging role of ACE2 in physiology and disease. J Pathol 2007; 212 : 1-11.
26. Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science2005; 309 : 1864-8.
27. Mathewson AC, Bishop A, Yao Y et al. Interaction of severe acute respiratory syndrome-coronavirus and NL63 coronavirus spike proteins with angiotensin converting enzyme-2. J Gen Virol 2008;89 : 2741-5.
28. Glowacka I, Bertram S, Herzog P et al. Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. J Virol 2010;84 : 1198-205.
29. Haga S, Yamamoto N, Nakai-Murakami C et al. Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry. Proc Natl Acad Sci U S A 2008; 105 : 7809-14.
30. Becker MM, Graham RL, Donaldson EF et al. Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice.Proc Natl Acad Sci U S A 2008; 105 : 19944-9.
31. Sheahan T, Rockx B, Donaldson E et al. Mechanisms of zoonotic severe acute respiratory syndrome coronavirus host range expansion in human airway epithelium. J Virol 2008; 82 : 2274-85.
32. Danilczyk U, Eriksson U, Crackower MA, Penninger JM. A story of two ACEs. J Mol Med (Berl) 2003; 81 : 227-34.
33. Simoes ESAC, Teixeira MM. ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis. Pharmacol Res 2016; 107 : 154-62.
34. Mendoza-Torres E, Oyarzun A, Mondaca-Ruff D et al. ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension. Ther Adv Cardiovasc Dis 2015; 9 : 217-37.
35. Nunes-Silva A, Rocha GC, Magalhaes DM et al. Physical Exercise and ACE2-Angiotensin-(1-7)-Mas Receptor Axis of the Renin Angiotensin System. Protein Pept Lett 2017; 24 : 809-16.
36. Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure. Circ Res 2016; 118 : 1313-26.
37. Xia H, Lazartigues E. Angiotensin-converting enzyme 2 in the brain: properties and future directions. J Neurochem 2008; 107 : 1482-94.
38. Uri K, Fagyas M, Kertesz A et al. Circulating ACE2 activity correlates with cardiovascular disease development. J Renin Angiotensin Aldosterone Syst 2016; 17 .
39. Niu MJ, Yang JK, Lin SS et al. Loss of angiotensin-converting enzyme 2 leads to impaired glucose homeostasis in mice. Endocrine 2008;34 : 56-61.
40. Bindom SM, Hans CP, Xia H et al. Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice.Diabetes 2010; 59 : 2540-8.
41. Rodrigues Prestes TR, Rocha NP, Miranda AS et al. The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research. Curr Drug Targets2017; 18 : 1301-13.
42. Padda RS, Shi Y, Lo CS et al. Angiotensin-(1-7): A Novel Peptide to Treat Hypertension and Nephropathy in Diabetes? J Diabetes Metab2015; 6 .
43. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020.
44. Ferrario CM, Jessup J, Chappell MC et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation2005; 111 : 2605-10.
45. Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 of the heart: From angiotensin I to angiotensin (1-7). Cardiovasc Res 2007;73 : 463-9.
46. Zhong JC, Ye JY, Jin HY et al. Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression. Regul Pept 2011; 166 : 90-7.
47. Sukumaran V, Veeraveedu PT, Gurusamy N et al. Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis.Int J Biol Sci 2011; 7 : 1077-92.
48. Karram T, Abbasi A, Keidar S et al. Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. Am J Physiol Heart Circ Physiol 2005; 289 : H1351-8.
49. Igase M, Strawn WB, Gallagher PE et al. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol2005; 289 : H1013-9.
50. Meng J, Xiao G, Zhang J et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension.Emerg Microbes Infect 2020; 9 : 757-60.
51. Kuster GM, Pfister O, Burkard T et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?Eur Heart J 2020.
52. Chappell MC. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure? Hypertension 2007;50 : 596-9.
53. Gallagher PE, Cook K, Soto-Pantoja D et al. Angiotensin peptides and lung cancer. Curr Cancer Drug Targets 2011; 11 : 394-404.
54. Perico L, Benigni A, Remuzzi G. Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade. Nephron 2020: 1-9.
55. Zou Z, Yan Y, Shu Y et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun 2014;5 : 3594.
56. Ramchand J, Patel SK, Srivastava PM et al. Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. PLoS One 2018; 13 : e0198144.
57. Kuba K, Imai Y, Ohto-Nakanishi T, Penninger JM. Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. Pharmacol Ther 2010;128 : 119-28.
58. Kuba K, Imai Y, Penninger JM. Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases. Circ J 2013; 77 : 301-8.
59. Imai Y, Kuba K, Rao S et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005;436 : 112-6.
60. Crackower MA, Sarao R, Oudit GY et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002;417 : 822-8.
61. Jia H. Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease. Shock 2016; 46 : 239-48.
62. Ye R, Liu Z. ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway. Exp Mol Pathol 2020; 113 : 104350.
63. Reddy R, Asante I, Liu S et al. Circulating angiotensin peptides levels in Acute Respiratory Distress Syndrome correlate with clinical outcomes: A pilot study. PLoS One 2019; 14 : e0213096.
64. Soro-Paavonen A, Gordin D, Forsblom C et al. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J Hypertens 2012; 30 : 375-83.
65. Gilbert A, Liu J, Cheng G et al. A review of urinary angiotensin converting enzyme 2 in diabetes and diabetic nephropathy. Biochem Med (Zagreb) 2019; 29 : 010501.
66. Qiao W, Wang C, Chen B et al. Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiology 2015;131 : 97-106.
67. Deshotels MR, Xia H, Sriramula S et al. Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism.Hypertension 2014; 64 : 1368-75.
68. Liu Y, Yang Y, Zhang C et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury.Sci China Life Sci 2020; 63 : 364-74.
69. Xie X, Chen J, Wang X et al. Age- and gender-related difference of ACE2 expression in rat lung. Life Sci 2006; 78 : 2166-71.
70. Yoon HE, Kim EN, Kim MY et al. Age-Associated Changes in the Vascular Renin-Angiotensin System in Mice. Oxid Med Cell Longev2016; 2016 : 6731093.
71. Du L, He Y, Zhou Y et al. The spike protein of SARS-CoV–a target for vaccine and therapeutic development. Nat Rev Microbiol 2009;7 : 226-36.
72. Shih YP, Chen CY, Liu SJ et al. Identifying epitopes responsible for neutralizing antibody and DC-SIGN binding on the spike glycoprotein of the severe acute respiratory syndrome coronavirus. J Virol 2006;80 : 10315-24.
73. Jeffers SA, Tusell SM, Gillim-Ross L et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 2004; 101 : 15748-53.
74. El-Sahly HM, Atmar RL, Glezen WP, Greenberg SB. Spectrum of clinical illness in hospitalized patients with ”common cold” virus infections.Clin Infect Dis 2000; 31 : 96-100.
75. Folz RJ, Elkordy MA. Coronavirus pneumonia following autologous bone marrow transplantation for breast cancer. Chest 1999;115 : 901-5.
76. Oxford JS, Bossuyt S, Lambkin R. A new infectious disease challenge: Urbani severe acute respiratory syndrome (SARS) associated coronavirus.Immunology 2003; 109 : 326-8.
77. Tse GM, To KF, Chan PK et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol 2004; 57 : 260-5.
78. Perlman S, Dandekar AA. Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol 2005;5 : 917-27.
79. Hung IF, Cheng VC, Wu AK et al. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis 2004; 10 : 1550-7.
80. Nishiura H. Early efforts in modeling the incubation period of infectious diseases with an acute course of illness. Emerg Themes Epidemiol 2007; 4 : 2.
81. Virlogeux V, Fang VJ, Wu JT et al. Brief Report: Incubation Period Duration and Severity of Clinical Disease Following Severe Acute Respiratory Syndrome Coronavirus Infection. Epidemiology 2015;26 : 666-9.
82. Virlogeux V, Park M, Wu JT, Cowling BJ. Association between Severity of MERS-CoV Infection and Incubation Period. Emerg Infect Dis2016; 22 : 526-8.
83. Cowling BJ, Muller MP, Wong IO et al. Alternative methods of estimating an incubation distribution: examples from severe acute respiratory syndrome. Epidemiology 2007; 18 : 253-9.
84. Fraser C, Riley S, Anderson RM, Ferguson NM. Factors that make an infectious disease outbreak controllable. Proc Natl Acad Sci U S A 2004; 101 : 6146-51.
85. Peak CM, Childs LM, Grad YH, Buckee CO. Comparing nonpharmaceutical interventions for containing emerging epidemics. Proc Natl Acad Sci U S A 2017; 114 : 4023-8.
86. Bai Y, Yao L, Wei T et al. Presumed Asymptomatic Carrier Transmission of COVID-19. Jama 2020.
87. Chan JF, Yuan S, Kok KH et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;395 : 514-23.
88. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020.Eurosurveillance 2020; 25 : 2000180.
89. Tong ZD, Tang A, Li KF et al. Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020. Emerg Infect Dis2020; 26 .
90. Young BE, Ong SWX, Kalimuddin S et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.Jama 2020.
91. Xu Y, Li X, Zhu B et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding.Nature Medicine 2020.